170 related articles for article (PubMed ID: 38325131)
1. Recent advances of Pin1 inhibitors as potential anticancer agents.
Bai Y; Yuan Z; Yuan S; He Z
Bioorg Chem; 2024 Mar; 144():107171. PubMed ID: 38325131
[TBL] [Abstract][Full Text] [Related]
2. Dual Roles of Pin1 in Cancer Development and Progression.
Han HJ; Choi BY; Surh YJ
Curr Pharm Des; 2017 Nov; 23(29):4422-4425. PubMed ID: 28671058
[TBL] [Abstract][Full Text] [Related]
3. An irreversible inhibitor of peptidyl-prolyl cis/trans isomerase Pin1 and evaluation of cytotoxicity.
Ieda N; Itoh K; Inoue Y; Izumiya Y; Kawaguchi M; Miyata N; Nakagawa H
Bioorg Med Chem Lett; 2019 Feb; 29(3):353-356. PubMed ID: 30585173
[TBL] [Abstract][Full Text] [Related]
4. Pin1 as an anticancer drug target.
Xu GG; Etzkorn FA
Drug News Perspect; 2009 Sep; 22(7):399-407. PubMed ID: 19890497
[TBL] [Abstract][Full Text] [Related]
5. Regulation of eukaryotic protein kinases by Pin1, a peptidyl-prolyl isomerase.
Chen XR; Igumenova TI
Adv Biol Regul; 2023 Jan; 87():100938. PubMed ID: 36496344
[TBL] [Abstract][Full Text] [Related]
6. [Recent advances in the study of pin1 and its inhibitors].
Zhang CJ; Zhang ZH; Xu BL; Wang YL
Yao Xue Xue Bao; 2008 Jan; 43(1):9-17. PubMed ID: 18357725
[TBL] [Abstract][Full Text] [Related]
7. Peptidyl-prolyl isomerases: functionality and potential therapeutic targets in cardiovascular disease.
Rostam MA; Piva TJ; Rezaei HB; Kamato D; Little PJ; Zheng W; Osman N
Clin Exp Pharmacol Physiol; 2015 Feb; 42(2):117-24. PubMed ID: 25377120
[TBL] [Abstract][Full Text] [Related]
8. The Multiple Roles of Peptidyl Prolyl Isomerases in Brain Cancer.
Stifani S
Biomolecules; 2018 Oct; 8(4):. PubMed ID: 30314361
[TBL] [Abstract][Full Text] [Related]
9. Rhein exhibits antitumorigenic effects by interfering with the interaction between prolyl isomerase Pin1 and c-Jun.
Cho JH; Chae JI; Shim JH
Oncol Rep; 2017 Mar; 37(3):1865-1872. PubMed ID: 28184937
[TBL] [Abstract][Full Text] [Related]
10. Phosphorylation-specific prolyl isomerase Pin1 as a new diagnostic and therapeutic target for cancer.
Finn G; Lu KP
Curr Cancer Drug Targets; 2008 May; 8(3):223-9. PubMed ID: 18473735
[TBL] [Abstract][Full Text] [Related]
11. The metabolic crosstalk between PIN1 and the tumour microenvironment.
Caligiuri I; Vincenzo C; Asano T; Kumar V; Rizzolio F
Semin Cancer Biol; 2023 Jun; 91():143-157. PubMed ID: 36871635
[TBL] [Abstract][Full Text] [Related]
12. The Peptidyl-Prolyl
Anto NP; Muraleedharan A; Nath PR; Sun Z; Keasar C; Livneh E; Braiman A; Altman A; Kong KF; Isakov N
Front Immunol; 2023; 14():1126464. PubMed ID: 36969236
[TBL] [Abstract][Full Text] [Related]
13. Biological Function of Pin1 in Vivo and Its Inhibitors for Preclinical Study: Early Development, Current Strategies, and Future Directions.
He S; Li L; Jin R; Lu X
J Med Chem; 2023 Jul; 66(14):9251-9277. PubMed ID: 37438908
[TBL] [Abstract][Full Text] [Related]
14. Prolyl isomerase Pin1: a catalyst for oncogenesis and a potential therapeutic target in cancer.
Ryo A; Liou YC; Lu KP; Wulf G
J Cell Sci; 2003 Mar; 116(Pt 5):773-83. PubMed ID: 12571275
[TBL] [Abstract][Full Text] [Related]
15. The role of Pin1 in the development and treatment of cancer.
Min SH; Zhou XZ; Lu KP
Arch Pharm Res; 2016 Dec; 39(12):1609-1620. PubMed ID: 27572155
[TBL] [Abstract][Full Text] [Related]
16. Design and Synthesis of Oligopeptidic Parvulin Inhibitors.
Relitti N; Prasanth Saraswati A; Carullo G; Papa A; Monti A; Benedetti R; Passaro E; Brogi S; Calderone V; Butini S; Gemma S; Altucci L; Campiani G; Doti N
ChemMedChem; 2022 Jun; 17(11):e202200050. PubMed ID: 35357776
[TBL] [Abstract][Full Text] [Related]
17. [Pin1: a multi-talented peptidyl prolyl cis-trans isomerase and a promising therapeutic target for human cancers].
Marsolier J; Weitzman JB
Med Sci (Paris); 2014; 30(8-9):772-8. PubMed ID: 25174754
[TBL] [Abstract][Full Text] [Related]
18. Phosphorylation-dependent prolyl isomerization: a novel signaling regulatory mechanism.
Zhou XZ; Lu PJ; Wulf G; Lu KP
Cell Mol Life Sci; 1999 Nov; 56(9-10):788-806. PubMed ID: 11212339
[TBL] [Abstract][Full Text] [Related]
19. Targeting prolyl isomerase Pin1 as a promising strategy to overcome resistance to cancer therapies.
Wu W; Xue X; Chen Y; Zheng N; Wang J
Pharmacol Res; 2022 Oct; 184():106456. PubMed ID: 36116709
[TBL] [Abstract][Full Text] [Related]
20. Mechanistic insights into Pin1 peptidyl-prolyl cis-trans isomerization from umbrella sampling simulations.
Di Martino GP; Masetti M; Cavalli A; Recanatini M
Proteins; 2014 Nov; 82(11):2943-56. PubMed ID: 25066180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
